logo-loader
OptiBiotix Health PLC

Transfer of certain SkinBioTherapeutics plc shares

/**/ p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .ak{size:595.3pt 841.9pt;margin:90.25pt 42.45pt 35.45pt 2.0cm;}div.ak{}p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}span.bx{font-size:10.0pt}span.bw{font-size:12.0pt}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: center}p.cc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;text-autospace:none}span.bu{letter-spacing: -.05pt}span.bt{letter-spacing:-.1pt}span.cd{letter-spacing:1.85pt} span.br{letter-spacing:-.05pt}span.bq{letter-spacing:-.15pt}span.ce{letter-spacing:1.9pt}span.bo{letter-spacing: -.15pt}span.cf{letter-spacing: 1.85pt}span.cg{letter-spacing:1.8pt}span.ch{letter-spacing:2.0pt}span.ci{letter-spacing: .1pt}span.bj{letter-spacing:.1pt}span.ag{} p.cj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: justify}span.bh{color:black}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;vertical-align:baseline}span.bf{color:black; letter-spacing:.05pt}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.bd{font-size:10.0pt; color:black}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.az{font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}span.ba{font-size:11.0pt;font-family:"Calibri","sans-serif"}table.cn{margin-left:-5.4pt;border-collapse:collapse} td.ax{width:334.1pt;padding:0cm 5.4pt 0cm 5.4pt}p.co{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}td.av{width:126.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}p.cq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.cr{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: right}p.cs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt}td.ar{width:228.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.aq{width:232.05pt;padding:0cm 5.4pt 0cm 5.4pt}td.ap{border:none} p.al{margin:0cm;margin-bottom:.0001pt;text-align:justify}span.an{font-size:11.0pt;font-family: "Calibri","sans-serif"}span.am{font-size: 11.0pt;font-family:"Calibri","sans-serif"} /**/
RNS Number : 0909H
OptiBiotix Health PLC
29 July 2019
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Transfer of certain SkinBioTherapeutics plc shares

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that a portion of its shareholding in SkinBioTherapeutics plc consisting of 20,438,496 ordinary shares representing 15.88% of SkinBioTherapeutics plc's total issued share capital, have been dematerialised and  transferred to a nominee CREST account (Pershing Nominees). OptiBiotix plc remains the beneficial owner of the transferred 20,438,496 ordinary shares.

 

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 49,794,190 representing 38.9% of SkinBioTherapeutics plc's total issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)


Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

 

finnCap (Broker)


Geoff Nash / Kate Bannatyne (Corporate Finance)

 

 

Tel: 020 7220 0500

Camille Gochez (Corporate Broking)

 


 

goetzpartners securities Limited

Tel: 0203 859 7725

Ulrich Kinzel  




Walbrook PR Ltd


Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCGMGZNKLMGLZM

Quick facts: OptiBiotix Health PLC

Price: 63

Market: AIM
Market Cap: £53.83 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE